Description:
Southwest Oncology Group S0600 Adverse Event Form Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5DA30D89-6264-0FC6-E040-BB89A643170F
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5DA30D89-6264-0FC6-E040-BB89A643170FKeywords:
Versions (4)
- 8/27/12 8/27/12 -
- 1/8/15 1/8/15 - Martin Dugas
- 1/9/15 1/9/15 - Martin Dugas
- 1/9/15 1/9/15 - Martin Dugas
Uploaded on:
January 9, 2015
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Colorectal Cancer NCT00499369 Toxicity - Southwest Oncology Group S0600 Adverse Event Form - 2813352v1.0
No Instruction available.
- StudyEvent: Southwest Oncology Group S0600 Adverse Event Form